Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Rapport Therapeutics, Inc.

NASDAQ: RAPP · Life Sciences · 15 alerts · CIK 2012593

Share price
$24.82Close, Nov 16
Market cap
$1.47B
Shares outstanding
59.28MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rapport Therapeutics, Inc. filings on SEC EDGAR ↗

7:33 PM ET Form 4
Insider Buying

Rapport Therapeutics Insider James Healy Buys $20.4M of Stock

James Healy bought 969,480 shares of Rapport Therapeutics, Inc. at $21.00 a share, worth $20.4M in total on Oct 28, 2026. Shares held after the trade: 25,267 (+37.8%).

Value
$20.4M
Shares
969,480
Average price
$21.00
Holding change
+37.8%
Trade date
Oct 28, 2026
4:01 PM ET Form 4
Insider Buying

Rapport Therapeutics Director Ramiro Sanchez Buys $98.5K of Stock

Ramiro Sanchez, Director, bought 3,600 shares of Rapport Therapeutics, Inc. at $27.35 a share, worth $98.5K in total on Oct 23, 2026. Shares held after the trade: 3,600.

Value
$98.5K
Shares
3,600
Price
$27.35
Role
Director
Trade date
Oct 23, 2026
4:57 PM ET Form 4
Insider Buying

Rapport Therapeutics Director Paul M. Silva Buys $99.6K of Stock

Paul M. Silva, Director, bought 3,680 shares of Rapport Therapeutics, Inc. at $27.07 a share, worth $99.6K in total on Oct 22, 2026. Shares held after the trade: 3,680.

Value
$99.6K
Shares
3,680
Price
$27.07
Role
Director
Trade date
Oct 22, 2026
4:57 PM ET Form 4
Insider Buying

Rapport Therapeutics Director Wendy B. Young Buys $100K of Stock

Wendy B. Young, Director, bought 3,789 shares of Rapport Therapeutics, Inc. at $26.39 a share, worth $100K in total on Oct 22, 2026. Shares held after the trade: 13,289 (+39.9%).

Value
$100K
Shares
3,789
Price
$26.39
Role
Director
Holding change
+39.9%
Trade date
Oct 22, 2026
4:57 PM ET Form 4
Insider Buying

Rapport Therapeutics Director Steven M. Paul Buys $974K of Stock

Steven M. Paul, Director, bought 35,714 shares of Rapport Therapeutics, Inc. at $27.28 a share, worth $974K in total on Oct 22, 2026. Shares held after the trade: 77,380 (+85.7%).

Value
$974K
Shares
35,714
Price
$27.28
Role
Director
Holding change
+85.7%
Trade date
Oct 22, 2026
4:56 PM ET Form 4
Insider Buying

Rapport Therapeutics Director John Maraganore Buys $249K of Stock

John Maraganore, Director, bought 9,411 shares of Rapport Therapeutics, Inc. at $26.38 to $26.92 a share (average $26.45) in 2 transactions, worth $249K in total on Oct 22, 2026. Shares held after the trade: 9,411 (+14.2%).

Value
$249K
Shares
9,411
Average price
$26.45
Role
Director
Holding change
+14.2%
Trade date
Oct 22, 2026
5:47 PM ET Form 4
Insider Buying

Rapport Therapeutics CFO Troy A. Ignelzi Buys $144K of Stock

Troy A. Ignelzi, CFO, bought 5,500 shares of Rapport Therapeutics, Inc. at $26.10 a share, worth $144K in total on Oct 21, 2026. Shares held after the trade: 15,500 (+55.0%).

Value
$144K
Shares
5,500
Price
$26.10
Role
CFO
Holding change
+55.0%
Trade date
Oct 21, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.